Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Experimental Hematology|December 17, 2002
Levels of E2A protein expression in B cell precursors are stage-dependent and inhibited by stem cell factor (c-kit ligand)Richard L Riley, Jennean Knowles, Anne M KingExperimental Gerontology|January 25, 2005
Pre-B cell loss in senescence coincides with preferential development of immature B cells characterized by partial activation and altered Vh repertoireEmily L Wilson, Anne M King, Erin M Sherwood, et al.European Journal of Immunology|November 25, 2003
A phenotypically distinct subset of immature B cells exhibits partial activation, increased survival, and preferential expression of VhS107Emily L Wilson, Erin M Sherwood, Anne M King, et al.Mechanisms of Ageing and Development|May 12, 2009
NK cells in the CD19- B220+ bone marrow fraction are increased in senescence and reduce E2A and surrogate light chain proteins in B cell precursorsAnne M King, Patricia Keating, Anjali Prabhu, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2007
Accelerated Notch-dependent degradation of E47 proteins in aged B cell precursors is associated with increased ERK MAPK activationAnne M King, Elaine Van der Put, Bonnie B Blomberg, et al.Oncogene|July 12, 2005
Caspase-9 and effector caspases have sequential and distinct effects on mitochondriaEnrique Cepero, Anne M King, Lane M Coffey, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 9, 2004
Decreased E47 in senescent B cell precursors is stage specific and regulated posttranslationally by protein turnoverElaine Van der Put, Daniela Frasca, Anne M King, et al.Seminars in Immunology|June 22, 2005
Deficient B lymphopoiesis in murine senescence: potential roles for dysregulation of E2A, Pax-5, and STAT5Richard L Riley, Elaine Van der Put, Anne M King, et al.Blood|February 22, 2007
CD28-mediated regulation of multiple myeloma cell proliferation and survivalNizar J Bahlis, Anne M King, Despina Kolonias, et al.Molecular Cancer Therapeutics|April 26, 2015
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody TherapeuticJeffrey D Kearns, Raghida Bukhalid, Mark Sevecka, et al.Pageof 1